NZ545570A - Amino acid prodrugs - Google Patents
Amino acid prodrugsInfo
- Publication number
- NZ545570A NZ545570A NZ545570A NZ54557004A NZ545570A NZ 545570 A NZ545570 A NZ 545570A NZ 545570 A NZ545570 A NZ 545570A NZ 54557004 A NZ54557004 A NZ 54557004A NZ 545570 A NZ545570 A NZ 545570A
- Authority
- NZ
- New Zealand
- Prior art keywords
- drug
- amino acid
- improved
- enhanced
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49133103P | 2003-07-29 | 2003-07-29 | |
PCT/US2004/024901 WO2005046575A2 (en) | 2003-07-29 | 2004-07-29 | Amino acid prodrugs |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ545570A true NZ545570A (en) | 2012-07-27 |
Family
ID=34590076
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ601780A NZ601780A (en) | 2003-07-29 | 2004-07-29 | Amino Acid Prodrugs |
NZ601772A NZ601772A (en) | 2003-07-29 | 2004-07-29 | Amino Acid Prodrugs |
NZ545570A NZ545570A (en) | 2003-07-29 | 2004-07-29 | Amino acid prodrugs |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ601780A NZ601780A (en) | 2003-07-29 | 2004-07-29 | Amino Acid Prodrugs |
NZ601772A NZ601772A (en) | 2003-07-29 | 2004-07-29 | Amino Acid Prodrugs |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1660017A4 (en) |
JP (2) | JP2007510621A (en) |
KR (3) | KR20120116991A (en) |
CN (1) | CN101123878A (en) |
AU (1) | AU2004289174B2 (en) |
CA (1) | CA2534342C (en) |
IL (1) | IL173382A0 (en) |
NZ (3) | NZ601780A (en) |
SG (2) | SG145693A1 (en) |
WO (1) | WO2005046575A2 (en) |
ZA (1) | ZA200600660B (en) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
KR20120116991A (en) * | 2003-07-29 | 2012-10-23 | 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 | Amino acid prodrugs |
US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
US7488747B2 (en) | 2003-12-29 | 2009-02-10 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
EP2754454A3 (en) * | 2004-01-07 | 2014-09-24 | Seikagaku Corporation | Non-steroidal anti-inflammatory drug derivatives |
US7241807B2 (en) | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
EP1964578A3 (en) * | 2005-05-05 | 2008-11-05 | Chroma Therapeutics Limited | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
JP5713535B2 (en) * | 2005-11-11 | 2015-05-07 | チャンドラン, ブイ., ラビChandran, V., Ravi | Pharmaceutical composition for reducing platelet aggregation, nutritional composition for reducing platelet aggregation, and food or beverage or aqueous liquid for reducing platelet aggregation |
JP5438975B2 (en) | 2006-01-06 | 2014-03-12 | サノビオン ファーマシューティカルズ インク | Tetralone monoamine reuptake inhibitor |
CN101394847B (en) | 2006-01-06 | 2017-05-24 | 塞普拉柯公司 | Cycloalkylamines as monoamine reuptake inhibitors |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
DK2013835T3 (en) | 2006-03-31 | 2015-12-14 | Sunovion Pharmaceuticals Inc | Preparation of chiral amides and AMINES |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
CN101657196A (en) * | 2006-07-06 | 2010-02-24 | 赛托维亚公司 | 4-aryl-chromene and application thereof as the replacement of Guang winter zymoexciter and inducer of apoptosis and anti-angiogenic dose |
CN1907954B (en) * | 2006-08-16 | 2011-11-23 | 重庆医科大学医药研究所 | Water-soluble derivative of anesthetic 2,6-diisopropyl phenol and preparation method thereof |
JP5043120B2 (en) | 2006-10-30 | 2012-10-10 | クロマ セラピューティクス リミテッド | Hydroxamates as inhibitors of histone deacetylase |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
JP5420534B2 (en) | 2007-05-31 | 2014-02-19 | サノビオン ファーマシューティカルズ インク | Phenyl-substituted cycloalkylamines as monoamine reuptake inhibitors |
WO2008157537A2 (en) * | 2007-06-19 | 2008-12-24 | Ironwood Pharmaceuticals, Inc | Compositions and methods of use for treating or preventing lipid related disorders |
EP2245012B1 (en) | 2008-02-29 | 2013-07-03 | Chroma Therapeutics Limited | Inhibitors of p38 map kinase |
TWI503101B (en) * | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | Body-associated receiver and method |
CA2747716A1 (en) | 2008-12-19 | 2010-06-24 | Pinnacle Pharmaceuticals, Inc. | Phenazopyridine compounds |
JP2012530764A (en) * | 2009-06-24 | 2012-12-06 | シャイア エルエルシー | Amino acid and peptide prodrugs of mexiletine and uses thereof |
PE20121282A1 (en) | 2009-11-12 | 2012-10-12 | Univ Michigan | SPIRO-OXINDOL ANTAGONISTS OF MDM2 |
MX2012008922A (en) | 2010-02-01 | 2012-10-05 | Proteus Digital Health Inc | Data gathering system. |
CN101906039B (en) * | 2010-06-23 | 2013-05-08 | 四川大学华西医院 | Hydroxy acid ester compound of substituted phenol, preparation method and application in medicine |
MX2010011006A (en) * | 2010-10-06 | 2012-04-18 | Senosiain S A De C V Lab | New salt of a pyrimidin derivative. |
WO2012065022A2 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
US20120196933A1 (en) * | 2010-12-23 | 2012-08-02 | Richard Franklin | Mexiletine prodrugs |
BR112013028983A2 (en) | 2011-05-11 | 2017-02-07 | Sanofi Sa | mdm2 antagonists spiro-oxindole |
FR2976944A1 (en) | 2011-06-21 | 2012-12-28 | Centre Nat Rech Scient | PEPTIDE PRODUCTS |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
EP2773378B1 (en) | 2011-10-31 | 2016-08-10 | Larsen, Claus Selch | Prodrugs of non-steroid anti-inflammatory agents (nsaids) |
PL2800738T3 (en) * | 2012-01-06 | 2020-10-19 | Novartis Ag | Heterocyclic compounds and methods for their use |
KR20220130239A (en) | 2012-01-18 | 2022-09-26 | 테크필즈 파마 코., 엘티디. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
JP2015519333A (en) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | Compositions and methods for the treatment of neurological disorders |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
EP2847158A4 (en) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
CA2873094A1 (en) * | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Prodrugs of anti-platelet agents |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175359A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
ES2797624T3 (en) | 2012-05-23 | 2020-12-03 | Cellix Bio Private Ltd | Composition for the treatment of inflammatory bowel disease |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
TWI601725B (en) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
JP2015529218A (en) | 2012-09-08 | 2015-10-05 | セリックスビオ プライヴェート リミテッド | Compositions and methods for the treatment of inflammation and lipid disorders |
CN102924398B (en) * | 2012-11-22 | 2015-11-18 | 安徽贝克生物制药有限公司 | For removing the method for the corresponding isomer of efavirenz |
CN103880754A (en) * | 2012-12-21 | 2014-06-25 | 西藏海思科药业集团股份有限公司 | Alkaline amino acid ester salt of propofol |
JP6498177B2 (en) | 2013-03-15 | 2019-04-10 | プロテウス デジタル ヘルス, インコーポレイテッド | Identity authentication system and method |
CN103263405B (en) * | 2013-05-08 | 2015-04-22 | 南京医科大学 | Medicinal composition for treating diabetes, and its application |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
CN103360240B (en) * | 2013-07-23 | 2015-03-11 | 西安新通药物研究有限公司 | Preparation method of high purity fenofibric acid |
CA2965941C (en) | 2013-09-20 | 2020-01-28 | Proteus Digital Health, Inc. | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
PT3701971T (en) | 2014-03-14 | 2022-10-03 | Biomolecular Holdings Llc | Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage |
CN103951557B (en) * | 2014-04-22 | 2016-06-08 | 徐州工业职业技术学院 | A kind of method with inorganic base for catalyst preparing fenofibrate |
WO2015184453A1 (en) * | 2014-05-30 | 2015-12-03 | Case Western Reserve University | Retinylamine derivitives for treatment of ocular disorders |
SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
JP6698643B2 (en) | 2014-09-29 | 2020-05-27 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
CN107108535B (en) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | Three-component salts of monomethyl fumarate with piperazine or ethylenediamine for the treatment of multiple sclerosis |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
CN104628554A (en) * | 2015-02-09 | 2015-05-20 | 徐州工程学院 | Fenofibric acid crystal form and preparation method thereof |
CN106146444A (en) * | 2015-04-03 | 2016-11-23 | 米文君 | A kind of new compound and application thereof |
CN105037180B (en) * | 2015-04-19 | 2017-10-10 | 安徽省逸欣铭医药科技有限公司 | Central analgesia noval chemical compound, the Preparation method and use of a kind of double action |
BR112018068886A2 (en) * | 2016-03-18 | 2019-01-22 | Caregen Co Ltd | finasteride conjugate with peptide |
JP6770008B2 (en) * | 2016-05-10 | 2020-10-14 | 浙江海正薬業股▲ふん▼有限公司Zhejiang Hisun Pharmaceutical CO.,LTD. | Water-soluble rapamycin derivative |
CN106316921B (en) * | 2016-08-19 | 2019-03-29 | 河南东泰制药有限公司 | A kind of preparation method of acemetacin |
CN108948140B (en) * | 2017-05-18 | 2021-10-26 | 首都医科大学 | warfarin-4-O-acetyl-Arg-AA eleven compounds, and synthesis, activity and application thereof |
CN108948139B (en) * | 2017-05-18 | 2021-10-26 | 首都医科大学 | warfarin-4-O-acetyl-Arg-AA compounds, their synthesis, activity and use |
UY38072A (en) | 2018-02-07 | 2019-10-01 | Novartis Ag | COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME |
CN108299219A (en) * | 2018-02-11 | 2018-07-20 | 中国农业大学 | O- is acylated serine derivative and the preparation method and application thereof |
CN116785447A (en) | 2018-09-14 | 2023-09-22 | 艾缇亚(上海)制药有限公司 | Novel conjugates of montelukast and peptides |
CN116041259A (en) * | 2023-01-13 | 2023-05-02 | 武汉科技大学 | Hydroxychloroquine derivative and preparation method thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
CA2102116A1 (en) * | 1991-05-31 | 1992-12-01 | Gary R. Schulte | Use of rapamycin prodrugs as immunosuppressant agents |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
JPH1143467A (en) * | 1997-05-14 | 1999-02-16 | Ikeda Mohandou:Kk | Fatty acid glyceride derivative and glyceride derivative, and their production |
IT1294205B1 (en) * | 1997-07-23 | 1999-03-24 | Farmigea Spa | PROCEDURE FOR THE SOLUBILIZATION IN WATER AND IN AQUEOUS VEHICLES OF PHARMACOLOGICALLY ACTIVE SUBSTANCES |
EP1309605A1 (en) * | 2000-08-18 | 2003-05-14 | The Board Of Trustees Of The University Of Illinois | Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv |
US20020160988A1 (en) * | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
EP1605946B1 (en) * | 2003-03-25 | 2008-05-28 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
KR20120116991A (en) * | 2003-07-29 | 2012-10-23 | 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 | Amino acid prodrugs |
-
2004
- 2004-07-29 KR KR1020127022817A patent/KR20120116991A/en not_active Application Discontinuation
- 2004-07-29 NZ NZ601780A patent/NZ601780A/en not_active IP Right Cessation
- 2004-07-29 JP JP2006522125A patent/JP2007510621A/en active Pending
- 2004-07-29 NZ NZ601772A patent/NZ601772A/en not_active IP Right Cessation
- 2004-07-29 KR KR1020137015399A patent/KR20130081319A/en not_active Application Discontinuation
- 2004-07-29 KR KR1020067002214A patent/KR20060073584A/en active Search and Examination
- 2004-07-29 SG SG200805624-4A patent/SG145693A1/en unknown
- 2004-07-29 NZ NZ545570A patent/NZ545570A/en not_active IP Right Cessation
- 2004-07-29 EP EP04816791A patent/EP1660017A4/en not_active Withdrawn
- 2004-07-29 CN CNA2004800282229A patent/CN101123878A/en active Pending
- 2004-07-29 SG SG2012005310A patent/SG178721A1/en unknown
- 2004-07-29 CA CA2534342A patent/CA2534342C/en not_active Expired - Fee Related
- 2004-07-29 WO PCT/US2004/024901 patent/WO2005046575A2/en active Application Filing
- 2004-07-29 AU AU2004289174A patent/AU2004289174B2/en not_active Ceased
-
2005
- 2005-01-23 ZA ZA200600660A patent/ZA200600660B/en unknown
-
2006
- 2006-01-26 IL IL173382A patent/IL173382A0/en unknown
-
2012
- 2012-10-01 JP JP2012219487A patent/JP2013035863A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2007510621A (en) | 2007-04-26 |
KR20120116991A (en) | 2012-10-23 |
JP2013035863A (en) | 2013-02-21 |
AU2004289174A2 (en) | 2005-05-26 |
WO2005046575A2 (en) | 2005-05-26 |
AU2004289174B2 (en) | 2011-05-19 |
WO2005046575A3 (en) | 2007-10-04 |
NZ601772A (en) | 2012-10-26 |
KR20130081319A (en) | 2013-07-16 |
SG145693A1 (en) | 2008-09-29 |
SG178721A1 (en) | 2012-03-29 |
EP1660017A2 (en) | 2006-05-31 |
ZA200600660B (en) | 2007-04-25 |
EP1660017A4 (en) | 2011-03-09 |
AU2004289174A1 (en) | 2005-05-26 |
CN101123878A (en) | 2008-02-13 |
IL173382A0 (en) | 2006-06-11 |
CA2534342C (en) | 2016-05-10 |
KR20060073584A (en) | 2006-06-28 |
NZ601780A (en) | 2012-10-26 |
CA2534342A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ545570A (en) | Amino acid prodrugs | |
WO2011163594A3 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
NZ597108A (en) | Prodrugs of nh-acidic compounds | |
WO2006058249A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
CA2511974A1 (en) | Pharmaceutical compositions comprising fentanyl for intranasal delivery | |
WO2007106550A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
WO2007121913A3 (en) | Pharmaceutical solution formulations for pressurised metered dose inhalers | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
NZ602675A (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
UA91512C2 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
WO2006050002A3 (en) | Compositions for controlled delivery of pharmaceutically active compounds | |
WO2007102888A3 (en) | Methods of treating cancer with doxazolidine and prodrugs thereof | |
HK1176318A1 (en) | Injection device | |
TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
WO2006131923A3 (en) | Novel salts of conjugated psychotropic drugs and processes of preparing same | |
WO2009111846A4 (en) | Mitochondrially delivered anti-cancer compounds | |
WO2005021721A3 (en) | Carboxylesterase inhibitors | |
JP2006516272A5 (en) | ||
MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
MY163762A (en) | Therapeutic agent for chronic renal failure | |
MX2007010886A (en) | Acarbose methods and formulations for treating chronic constipation. | |
UA93365C2 (en) | Injectable preparations of diclofenic and its pharmaceutically acceptable salts, and processes for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 JUL 2017 BY COMPUTER PACKAGES INC Effective date: 20140729 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2018 BY COMPUTER PACKAGES INC Effective date: 20170801 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2019 BY COMPUTER PACKAGES INC Effective date: 20180703 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2020 BY COMPUTER PACKAGES INC Effective date: 20190718 |
|
LAPS | Patent lapsed |